NTNU Health at the Faculty of Natural Sciences

NTNU Health at the Faculty of Natural Sciences

Collage with a photo of a researcher in the lab and Realfagbygget. Photos collage
Photo: Per Henning/NTNU

NTNU Health is one of four Strategic Research Areas 2014–2023 at the Norwegian University of Science and Technology (NTNU). The project forms networks across faculties and departments and bring researchers together to work on cross-disciplinary subjects. NTNU Health's main research topics

Diagnostics and therapy

Diagnostics and therapy

Neuroscience - Bionanotechnology - Regenerative medicine - Biotechnology - Medical imaging - Palliative medicine - Inflammation - Age and lifestyle related diseases and major widespread diseases

Diagnostics and therapy knowledge areas

Research team

Research team

NTNU Health at the Faculty of Natural Sciences (NV) has a number of researchers working on topics related to Diagnostics and Therapy.


Per Bruheim

Per Bruheim focuses on deep phenotyping of prokaryotic and eukaryotic systems using advanced cultivation technology and mass spectrometry based metabolomics and fluxomics. Current research activities involves microbial model systems (Pseudomonas, E. coli, Streptomyces, S. cerevisiae), human cell lines and body fluids, the latter for biomarker identification. Per Bruheim works at the Department of Biotechnology and Food Science (IBT).


Pål Erik Goa

Pål Erik Goa's current research is within clinical applications of MRI, in particular diffusion weighted MRI in diagnosis and differentiation of cancer. He has a close collaboration with St.Olavs Hospital where he holds an adjunct position, and he also works closely with the MR-group at the Medical Faculty. Pål Erik Goa is associate professor in medical physics and works at Department of Physics (IFY).


Elisabeth Jacobsen

Elisabeth Jacobsen uses enzymes as catalysts in organic synthesis of enantiomerically pure drugs and other biologically active molecules. Several of the most sellings drugs worldwide are manufactured with single enantiomers as the active pharmaceutical ingredient (API), for instance the cholesterol lowering drug Lipitor. Since the "wrong" enantiomer (mirror image) of a drug may cause side effects or even lethal effects, it has become a demand that the most active enantiomer API of a racemic drug should be available on the market. Enzyme catalysis is an effective and environmentally friendly method in order to obtain organic compounds with high enantiopurity. At the moment the research focuses mostly on beta-blockers. Elisabeth Jacobsen works at Department of  Chemistry (IKJ).


Martin Kuiper

Martin Kuiper and the Kuiper group develops approaches and software tools for the analysis of biological data, and the use of ontologies and semantic web technologies for the integration of biological knowledge. In close collaboration with the Lægreid group at the Department of Cancer Research and Molecular Medicine (IKMM), Kuiper contributes to a biomedical knowledge commons for construction of computer models of cancer cells that allow in-silico prediction of drug effects. Martin Kuiper works at Department of Biology (IBI). Kuiper's research team: Systems Biology


Pawel Sikorski

Pawel Sikorski is working in the the fields of biopolymers, biomaterials and the application of nanotechnology in biophysics and cell biology research. He is interested in developing strategies to make new, functional, hydrogel based materials, as well as understanding complex physical phenomena involved in the process, in material characterization and micro and nano-fabrication. Pawel Sikorski works at Department of Physics (IFY). Sikorski's research team: Bionanotechnology